GC Biopharma said it recently participated in a major academic event in the U.S. to introduce the technical characteristics of its immunoglobulin drug Alyglo in the U.S. market.

The company held two academic presentations on Alyglo to immunology experts, nurses, and others in the U.S.

According to GC Biopharma, the company shared information on Alyglo's Cation Exchange Chromatography (CEX) technology with immunology professionals at the Clinical Immunology Society Annual Meeting (CIS 2025), held in Philadelphia from May 1 to 4, local time.

Ryan Dorfman, COO of Prolytix, a CRO, explained that differences between immunoglobulin products can lead to adverse events in some patients, including hypersensitivity reactions, blood clots, and decreased kidney function.

He emphasized that GC Biopharma's Alyglo incorporates technology that removes thrombogenic factors (FXI/FXIa) below the limit of detection.

At the Infusion Nurses Society's annual meeting (INS 2025), held from April 25 to 29 in Las Vegas, the head of clinical education at GC Biopharma USA trained about 600 nurses on how to administer the treatment.

Alyglo is a 10 percent formulation of intravenous immunoglobulin (IVIG) developed by GC Biopharma for the treatment of primary immunodeficiency diseases, including congenital immunodeficiency and immune thrombocytopenia. GC Biopharma is pursuing the U.S. market for Alyglo, which was granted marketing authorization by the U.S. FDA in 2023.

Alyglo is currently on the formularies of major U.S. payers, and GC Biopharma is building a network of payers, PBMs, specialty pharmacies, and distributors. Prescribing began in the third quarter of 2024, and approximately 400 patients are currently receiving Alyglo.

GC Biopharma expects to reach 1,000 prescribed patients by the end of this year and aims to achieve annual sales of $100 million in the U.S. market.

“The technical characteristics of Alyglo are being introduced to American doctors and patients, and the number of prescriptions is gradually increasing,” said Lee Woo-jin, CEO of GC Biopharma USA.